Vincerx Pharma Highlights VIP152 Preclinical, Clinical Data In Gynecological Cancers


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Vincerx Pharma Inc (NASDAQ:VINC) announced a poster presentation of preclinical and preliminary clinical data on VIP152 in gynecologic cancer cell lines and patients with gynecologic malignancies, respectively.

  • The data were shared at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • A 10-fold range of sensitivity to VIP152 was observed in cisplatin-sensitive and cisplatin-resistance ovarian, uterus, uterus/cervix, and vulva cancer cell lines demonstrating the cytotoxic effects of VIP152.
  • Antitumor efficacy was observed following a single 17.5 mg/kg dose of VIP152 monotherapy.
  • VIP152 treatment administered once weekly showed predictable pharmacokinetic properties. It showed a significant reduction in MYC protein expression in patient-derived ovarian and endometrial cancer tissue samples and downregulation of CDK9-regulated genes expression in the blood of patients with gynecologic cancer.
  • At their first assessment, four out of seven patients with gynecologic cancers treated with VIP152 had stable disease, including all 3 of the MYC-amplified patients. One patient remains on treatment.
  • Price Action: VINC shares closed 5.76% lower at $3.60 on Friday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPreclinical Phase